H.R. 3491

119th Congress

In Committee

DeOndra Dixon INCLUDE Project Act of 2025

Sponsored byDemocrat:Rep. DeGette, Diana [D-CO-1]CO· Introduced 19 mai 2025

18

Cosponsors

15

Actions

0

Amendments

1

Committees

Since introduced

Introduced
Committee
Passed Chamber
Passed Both
Enacted
Step 1 of 0
Latest action

Received in the Senate and Read twice and referred to the Committee on Health, Education, Labor, and Pensions.

21 juillet 2026·2 days ago

Summary

Reported to House · Updated 15 juillet 2026

DeOndra Dixon INCLUDE Project Act of 2025

This bill provides statutory authority for a program of the National Institutes of Health (NIH) that carries out research and training relating to Down syndrome, including with respect to co-occurring conditions and improving the quality of life of affected individuals. The NIH must implement the program in consultation with relevant stakeholders and avoid duplicating existing NIH Down syndrome research.

Biennially, the NIH must submit to Congress a report cataloging the research, including results that may be used in medical care or clinical research.

Timeline

15 actions

  1. Received in the Senate and Read twice and referred to the Committee on Health, Education, Labor, and Pensions.

    21 juillet 2026 · IntroReferral

  2. On motion to suspend the rules and pass the bill Agreed to by voice vote.

    20 juillet 2026 · Floor

  3. Passed/agreed to in House: On motion to suspend the rules and pass the bill Agreed to by voice vote.

    20 juillet 2026 · Floor

  4. Mr. Guthrie moved to suspend the rules and pass the bill.

    20 juillet 2026 · Floor

  5. Considered under suspension of the rules.

    20 juillet 2026 · Floor

  6. Mr. Guthrie moved to suspend the rules and pass the bill.

    20 juillet 2026 · Floor

  7. DEBATE - The House proceeded with forty minutes of debate on H.R. 3491.

    20 juillet 2026 · Floor

  8. Motion to reconsider laid on the table Agreed to without objection.

    20 juillet 2026 · Floor

  9. Reported by the Committee on Energy and Commerce. H. Rept. 119-722.

    2 juillet 2026 · Committee

  10. Reported by the Committee on Energy and Commerce. H. Rept. 119-722.

    2 juillet 2026 · Committee

  11. Placed on the Union Calendar, Calendar No. 627.

    2 juillet 2026 · Calendars

  12. Placed on the Union Calendar, Calendar No. 627.

    2 juillet 2026 · Calendars

  13. Reported by the Committee on Energy and Commerce. H. Rept. 119-722.

    2 juillet 2026 · Committee

  14. Reported by the Committee on Energy and Commerce. H. Rept. 119-722.

    2 juillet 2026 · Committee

  15. Reported by the Committee on Energy and Commerce. H. Rept. 119-722.

    2 juillet 2026 · Committee

  16. Committee Consideration and Mark-up Session Held

    21 mai 2026 · Committee

  17. Committee Consideration and Mark-up Session Held

    21 mai 2026 · Committee

  18. Committee Consideration and Mark-up Session Held

    21 mai 2026 · Committee

  19. Committee Consideration and Mark-up Session Held

    21 mai 2026 · Committee

  20. Ordered to be Reported by the Yeas and Nays: 46 - 0.

    21 mai 2026 · Committee

Sponsorship

18 cosponsors

Cosponsors

  • Democrat1267%
  • Republican633%

Classification

Policy area

Health

Legislative subjects

Congressional oversightGeneticsHereditary and development disordersMedical researchResearch administration and funding

Committees

1

  • Energy and Commerce Committee

    House · Standing

    • Referred To19 May 2025
    • Markup By21 May 2026

Cosponsor momentum

Cumulative over time

Cosponsors grew from 5 on 19 mai 2025 to 18 on 16 mars 2026.

Pelosi Tracker
© 2026 - Tous droits réservés. Propulsé par Vantara Labs
Ce site web est une plateforme indépendante et tierce. Il n'est pas affilié à, approuvé par ou associé de quelque manière que ce soit à Nancy Pelosi, son bureau ou ses représentants. Toute utilisation de son nom est uniquement à des fins de discussion d'informations publiques disponibles.Les informations fournies sur ce site web sont uniquement à des fins informatives et éducatives et ne sont pas destinées à servir de conseils financiers ou d'investissement, ni ne doivent être interprétées comme tels. Les données présentées ici proviennent de déclarations et dossiers publics. Bien que nous nous efforcions d'assurer l'exactitude, l'actualité et l'exhaustivité, nous ne garantissons pas que toutes les informations sont exemptes d'erreurs ou à jour.Le support est disponible en anglais. Certaines traductions sont automatiques.